ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.48% | -3.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.48% | -3.51% | |||
| Cost of Revenue | -11.74% | 2.08% | |||
| Gross Profit | 35.34% | -7.89% | |||
| SG&A Expenses | -3.38% | 4.47% | |||
| Depreciation & Amortization | -82.98% | -2.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.45% | 1.16% | |||
| Operating Income | 55.19% | -11.23% | |||
| Income Before Tax | 92.26% | -670.62% | |||
| Income Tax Expenses | 108.66% | -472.29% | |||
| Earnings from Continuing Operations | 89.96% | -709.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.96% | -709.93% | |||
| EBIT | 55.19% | -11.23% | |||
| EBITDA | 54.75% | -19.13% | |||
| EPS Basic | 92.80% | -593.23% | |||
| Normalized Basic EPS | 59.47% | 9.84% | |||
| EPS Diluted | 92.80% | -593.23% | |||
| Normalized Diluted EPS | 59.47% | 9.84% | |||
| Average Basic Shares Outstanding | 39.42% | 16.77% | |||
| Average Diluted Shares Outstanding | 39.42% | 16.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||